A descriptive report of outcomes of primary mucinous ovarian cancer patients receiving either an adjuvant gynecologic or gastrointestinal chemotherapy regimen Journal Article

   

Authors:	Schlappe, B. A.; Zhou, Q. C.; O'Cearbhaill, R.; Iasonos, A.; Soslow, R. A.; Abu-Rustum, N. R.; Mueller, J. J.
Article Title:	A descriptive report of outcomes of primary mucinous ovarian cancer patients receiving either an adjuvant gynecologic or gastrointestinal chemotherapy regimen
Abstract:	Objective We described progression-free survival and overall survival in patients with primary mucinous ovarian cancer receiving adjuvant gynecologic versus gastrointestinal chemotherapy regimens. Methods We identified all primary mucinous ovarian cancer patients receiving adjuvant gynecologic or gastrointestinal chemotherapy regimens at a single institution from 1994 to 2016. Gynecologic pathologists using strict pathologic/clinical criteria determined diagnosis. Adjuvant therapy was coded as gynecologic or gastrointestinal based on standard agents and schedules. Clinical/pathologic/treatment characteristics were recorded. Wilcoxon rank-sum test was used for continuous variables, and Fisher's exact test for categorical variables. Progression-free and overall survival were calculated using the Kaplan-Meier method, applying landmark analysis. Results Of 62 patients identified, 21 received adjuvant chemotherapy: 12 gynecologic, 9 gastrointestinal. Median age (in years) at diagnosis: 58 (range 25-68) gynecologic cohort, 38 (range 32-68) gastrointestinal cohort (p=0.13). Median body mass index at first post-operative visit: 25 kg/m 2 (range 18-31) gynecologic cohort, 23 kg/m 2 (range 18-31) gastrointestinal cohort (p=0.23). History of smoking: 6/12 (50%) gynecologic cohort, 3/9 (33%) gastrointestinal cohort (p=0.66). Stage distribution in gynecologic and gastrointestinal cohorts, respectively: stage I: 9/12 (75%) and 3/9 (33%); stage II: 2/12 (17%) and 1/9 (11%); stage III: 1/12 (8%) and 5/9 (56%) (p=0.06). Grade distribution in gynecologic and gastrointestinal cohorts, respectively: grade 1: 8/12 (67%) and 1/9 (13%); grade 2/3: 4/12 (33%) and 7/9 (88%) (p=0.03). Three-year progression-free survival: 90.9% (95% CI 50.8% to 98.7 %) gynecologic, 53.3% (95% CI 17.7% to 79.6%) gastrointestinal. Three-year overall survival: 90.9% (95% CI 50.8% to 98.7%) gynecologic, 76.2% (95% CI 33.2% to 93.5%) gastrointestinal. Conclusion Ongoing international collaborative research may further define associations between chemotherapy regimens and survival. © 2019 IGCS and ESGO.
Keywords:	chemotherapy; gastrointestinal; oncologic outcomes; mucinous ovarian cancer
Journal Title:	International Journal of Gynecological Cancer
Volume:	29
Issue:	5
ISSN:	1048-891X
Publisher:	Lippincott Williams & Wilkins
Date Published:	2019-06-01
Start Page:	904
End Page:	909
Language:	English
DOI:	10.1136/ijgc-2018-000150
PUBMED:	31097512
PROVIDER:	scopus
PMCID:	PMC7385730
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85067803322&doi=10.1136%2fijgc-2018-000150&partnerID=40&md5=cfa21285639e9d3ac8e7273abf77181f
Notes:	Article -- Export Date: 2 August 2019 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/150163